WO2003047567A8 - STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG - Google Patents

STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG

Info

Publication number
WO2003047567A8
WO2003047567A8 PCT/EP2002/013446 EP0213446W WO03047567A8 WO 2003047567 A8 WO2003047567 A8 WO 2003047567A8 EP 0213446 W EP0213446 W EP 0213446W WO 03047567 A8 WO03047567 A8 WO 03047567A8
Authority
WO
WIPO (PCT)
Prior art keywords
acid
aqueous solution
solution
stable
derivatives
Prior art date
Application number
PCT/EP2002/013446
Other languages
English (en)
French (fr)
Other versions
WO2003047567A1 (de
Inventor
Hans Schuhbauer
Stephan Winkler
Margot Rudholzner
Roswitha Mussner
Evi Huber
Original Assignee
Degussa
Hans Schuhbauer
Stephan Winkler
Margot Rudholzner
Roswitha Mussner
Evi Huber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa, Hans Schuhbauer, Stephan Winkler, Margot Rudholzner, Roswitha Mussner, Evi Huber filed Critical Degussa
Priority to US10/495,600 priority Critical patent/US20040266858A1/en
Priority to EP02804200A priority patent/EP1450789A1/de
Priority to JP2005501541A priority patent/JP2006502245A/ja
Publication of WO2003047567A1 publication Critical patent/WO2003047567A1/de
Publication of WO2003047567A8 publication Critical patent/WO2003047567A8/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Cosmetics (AREA)

Abstract

Die vorliegende Erfindung beschreibt eine stabile, saure, wässrige Lösung von α-Liponsäure oder deren Derivaten. Ein über der eigentlichen Löslichkeit der eingesetzten Liponsäure-Komponente liegender Gehalt in wässriger Lösung wird dabei vorzugsweise durch ein Herstellungsverfahren erreicht, bei dem in einer ersten Stufe eine Stammlösung der Liponsäure-Komponente in Wasser mit Hilfe einer Base vorgelegt wird, dann gegebenenfalls durch Verdünnen und Temperieren diese Stammlösung in den gewünschten Konzentrations- und Temperaturbereich gebracht wird und schliesslich der gewünschte pH-Wert der Lösung durch Zugabe einer Säure eingesellt wird. Die u.a. auf diese Weise erhaltene Lösung ist aufgrund ihrer stabilen Eigenschaften hervorragend für die Verwendung zu pharmazeutischen, kosmetischen, dietätischen oder auch technischen Zwecken, beispielsweise zur Minderung photochemischer Einflüsse, geeignet.
PCT/EP2002/013446 2001-12-03 2002-11-28 STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG WO2003047567A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/495,600 US20040266858A1 (en) 2001-12-03 2002-11-28 Stable, acid, aqueous solution containing alpha-liponic acid (derivatives), method for the production thereof and use of the same
EP02804200A EP1450789A1 (de) 2001-12-03 2002-11-28 STABILE, SAURE, W SSRIGE L SUNG ENTHALTEND a-LIPONS URE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE V ERWENDUNG
JP2005501541A JP2006502245A (ja) 2001-12-03 2002-11-28 α−リポ酸（誘導体）を含有している安定な酸性水溶液、その製造方法並びにその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159245.0 2001-12-03
DE10159245A DE10159245A1 (de) 2001-12-03 2001-12-03 Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung

Publications (2)

Publication Number Publication Date
WO2003047567A1 WO2003047567A1 (de) 2003-06-12
WO2003047567A8 true WO2003047567A8 (de) 2004-03-25

Family

ID=7707822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013446 WO2003047567A1 (de) 2001-12-03 2002-11-28 STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG

Country Status (5)

Country Link
US (1) US20040266858A1 (de)
EP (1) EP1450789A1 (de)
JP (1) JP2006502245A (de)
DE (1) DE10159245A1 (de)
WO (1) WO2003047567A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10318045A1 (de) * 2003-04-17 2004-11-04 Basf Ag Stabile Ammoniumsalze der alpha-Liponsäure, ihre Herstellung und Verwendung
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
DE102004050353A1 (de) * 2004-10-15 2006-04-20 Basf Ag Verwendung stabiler Ammoniumsalze der Liponsäure zur Behandlung diabetischer und weiterer Störungen
EP1707217A1 (de) * 2004-12-17 2006-10-04 Wacker Chemie AG Methode zur Herstellung eines Alpha-Liponsaure/cyclodextrin Komplexes sowie das hersgestellte Produkt
CN1853626B (zh) * 2005-04-29 2010-10-06 上海医药工业研究院 一种供注射用的硫辛酸冻干制剂
JP4910428B2 (ja) * 2006-03-02 2012-04-04 大正製薬株式会社 内服液剤組成物
JP5125146B2 (ja) * 2006-03-02 2013-01-23 大正製薬株式会社 内服液剤
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
RU2011124739A (ru) * 2008-12-01 2013-01-10 Инваск Терапьютикс, Инк. Композиции, содержащие ингибиторы системы ренин-ангиотензин альдостерона и соединения липоевой кислоты, и их применение для лечения заболеваний, связанных с системой ренин-ангиотензин альдостерона
JP6054291B2 (ja) * 2011-05-31 2016-12-27 株式会社ナノエッグ 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物
PL3244885T3 (pl) * 2015-01-13 2019-08-30 Lo.Li. Pharma S.R.L. Kwas liponowy do leczenia lub zapobiegania zagrożeniu poronieniem lub przedwczesnym porodem
KR20180052130A (ko) * 2015-09-24 2018-05-17 앙코르 비전, 인코포레이티드 리포산 콜린 에스테르 조성물, 및 생체적합성 안과용 제형의 생성 방법
CN109925280B (zh) * 2017-12-19 2021-06-01 大连中信药业股份有限公司 一种硫辛酸注射液及其制备方法
CN111893759B (zh) * 2020-07-30 2023-03-24 江苏阳光股份有限公司 一种精纺羊毛面料的抗静电整理工艺及精纺羊毛面料

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
EP0318891B1 (de) * 1987-12-04 1992-01-02 ASTA Medica Aktiengesellschaft Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren
ES2115589T3 (es) * 1989-11-09 1998-07-01 Asta Medica Ag Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa.
DE59308496D1 (de) * 1992-09-08 1998-06-10 Basf Ag Verbessertes Verfahren zur Herstellung von R/S-gamma-Liponsäure oder R/S-alpha-Liponsäure
CZ365996A3 (en) * 1994-06-15 1997-10-15 Procter & Gamble Use of mercapto derivatives for preparing pharmaceutical preparation for making lighter of skin
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
PT1093337E (pt) * 1998-08-21 2007-07-02 Muscletech Res And Dev Inc Suplemento alimentar compreendendo ácido lipóico e creatina e métodos para a sua utilização
KR100390630B1 (ko) * 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
DE19938621A1 (de) * 1999-08-14 2001-02-22 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von lösemittelfreier alpha-Liponsäure
US6254898B1 (en) * 2000-05-25 2001-07-03 Protective Factors, Inc. Nutraceutical composition for protection against solar radiation

Also Published As

Publication number Publication date
DE10159245A1 (de) 2003-06-18
US20040266858A1 (en) 2004-12-30
WO2003047567A1 (de) 2003-06-12
JP2006502245A (ja) 2006-01-19
EP1450789A1 (de) 2004-09-01

Similar Documents

Publication Publication Date Title
WO2003047567A8 (de) STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG
BRPI0509407A (pt) composição de bebida ácida e processos de sua fabricação
WO2002096457A3 (en) Stable liquid formulations of antibodies
NO20033677L (no) 2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer
RS20050669A (en) Novel process for the preparation of roflumilast
DE60100433D1 (de) Proteinbeschichtung
KR910000518A (ko) 안정화 이산화염소 수용액의 제조 방법
BR0300826A (pt) Formulação antitumor com base em paclitaxel melhorada
WO2002009713A3 (de) Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
HUP9903334A2 (hu) Eljárás morfológiailag egységes mikrokapszulák előállítására, valamint az ezzel az eljárással előállított mikrokapszulák
NO20001886L (no) Stabile, krystallinske salter av 5-metyltetrahydrofolsyre og fremgangsmÕte til fremstilling derav
WO2003055878A8 (de) 2-heteroarylcarbonsäureamide
RO117145B1 (ro) Emulsie sau soluţie apoasă, mucoadezivă
HUP0400387A2 (hu) A tobramicin aeroszol kialakítására optimalizált készítménye és eljárás az előállítására
DE69933518D1 (de) Stabile flüssige zusammensetzungen von kalzium-ascorbat und verfahren zu ihrer herstellung und verwendung
MY149528A (en) A method of treating an aqueous system containing or in contact with metal sulphide scale
MXPA02011817A (es) Solucion acuosa de acido ascorbico y metodo para producir la misma.
ATE353341T1 (de) Lösungsverzögerte celluloseether und ein verfahren zu ihrer herstellung
ES2190794T3 (es) Procedimiento para la preparacion de disoluciones acuosas de dioxido de cloro.
AU2001264234A1 (en) Microcapsule suspension liquid and process for production thereof
WO2002000183A3 (en) Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
ATE242818T1 (de) Verfahren zur bekämpfung von mikroorganismen in einem zuckerhaltigen, wässrigen prozessmedium
WO2004012838A3 (en) Electrodionization method
PT1543826E (pt) Solução aquosa concentrada de ambroxol
HUP0401234A2 (hu) Pravastatin stabil gyógyászati kompozíciója és eljárás az előállítására

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 24/2003 UNDER (81) ADD "JP"

WWE Wipo information: entry into national phase

Ref document number: 2002804200

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10495600

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005501541

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002804200

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002804200

Country of ref document: EP